Sanders, Melinda E.

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 5,592

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology

Breast Cancer Treatment StudiesBRCA gene mutations in cancer

Cited by 3,079

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

Zhang, H., Liu, T., Zhang, Z., Payne, S. H., Zhang, B., McDermott, J. E., Zhou, J.-Y., Petyuk, V. A., Chen, L., Ray, D., et al. (2016) · Cell

Ovarian cancer diagnosis and treatmentAdvanced Proteomics Techniques and Applications

Cited by 1,029

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities

Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell

Advanced Proteomics Techniques and ApplicationsCancer Genomics and Diagnostics

Cited by 799

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 536

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 275

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine

Breast Cancer Treatment StudiesProtein Tyrosine Phosphatases

Cited by 262

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J.-E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersAutoimmune Neurological Disorders and Treatments

Cited by 176

PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses

Sai, J., Owens, P., Novitskiy, S. V., Hawkins, O. E., Vilgelm, A. E., Yang, J., Sobolik, T., Lavender, N., Johnson, A. C., McClain, C., et al. (2017) · Clinical Cancer Research

PI3K/AKT/mTOR signaling in cancerCancer Immunotherapy and Biomarkers

Cited by 138